[company_age]9.0[/company_age][employees]11-50 employees[/employees][funding]Series B[/funding][description]Hylomorph is a cutting-edge medical technology company specializing in biomaterials engineering. Their focus lies in optimizing the interface between implants and surrounding biological tissues, aiming to prevent post-operative complications associated with implantable medical devices. This Swiss company, founded on the basis of research conducted at the prestigious Swiss Federal Institute of Technology (ETH Zurich), boasts a proprietary technology called CellSense. Hylomate, their first product, has shown remarkable success in pre-clinical trials by limiting foreign body reactions and fibrotic buildup. Currently, Hylomate is undergoing its first-in-human clinical trials in Germany. Hylomorph's mission is to improve the quality of life for patients and enhance the quality of care provided by healthcare professionals. Their dedication to innovation and commitment to addressing unmet medical needs sets them apart as a leader in the field of biomaterials and medical device development.[/description][ps]Hylomate, a biomaterial envelope for Cardiac Rhythm Management Devices.[/ps]